Fulgent Genetics (FLGT) Capital Expenditures (2016 - 2026)
Fulgent Genetics' Capital Expenditures history spans 12 years, with the latest figure at $5.2 million for Q1 2026.
- On a quarterly basis, Capital Expenditures rose 10.26% to $5.2 million in Q1 2026 year-over-year; TTM through Mar 2026 was $23.1 million, a 43.73% decrease, with the full-year FY2025 number at $22.6 million, down 44.01% from a year prior.
- Capital Expenditures hit $5.2 million in Q1 2026 for Fulgent Genetics, down from $20.5 million in the prior quarter.
- Over the last five years, Capital Expenditures for FLGT hit a ceiling of $37.8 million in Q4 2024 and a floor of -$2.3 million in Q3 2024.
- Historically, Capital Expenditures has averaged $6.4 million across 5 years, with a median of $4.7 million in 2025.
- Biggest five-year swings in Capital Expenditures: skyrocketed 1117.87% in 2024 and later crashed 393.95% in 2025.
- Tracing FLGT's Capital Expenditures over 5 years: stood at $4.7 million in 2022, then tumbled by 34.22% to $3.1 million in 2023, then skyrocketed by 1117.87% to $37.8 million in 2024, then tumbled by 45.8% to $20.5 million in 2025, then tumbled by 74.63% to $5.2 million in 2026.
- Business Quant data shows Capital Expenditures for FLGT at $5.2 million in Q1 2026, $20.5 million in Q4 2025, and -$510000.0 in Q3 2025.